U.S. markets close in 5 hours 41 minutes
  • S&P 500

    4,181.48
    -40.38 (-0.96%)
     
  • Dow 30

    33,353.10
    -470.35 (-1.39%)
     
  • Nasdaq

    14,077.41
    -83.94 (-0.59%)
     
  • Russell 2000

    2,257.95
    -29.51 (-1.29%)
     
  • Crude Oil

    71.95
    +0.91 (+1.28%)
     
  • Gold

    1,773.60
    -1.20 (-0.07%)
     
  • Silver

    26.08
    +0.22 (+0.87%)
     
  • EUR/USD

    1.1874
    -0.0037 (-0.31%)
     
  • 10-Yr Bond

    1.5180
    +0.0070 (+0.46%)
     
  • GBP/USD

    1.3828
    -0.0096 (-0.69%)
     
  • USD/JPY

    110.4000
    +0.1690 (+0.15%)
     
  • BTC-USD

    36,753.30
    -1,757.01 (-4.56%)
     
  • CMC Crypto 200

    906.75
    -33.20 (-3.53%)
     
  • FTSE 100

    7,042.32
    -111.11 (-1.55%)
     
  • Nikkei 225

    28,964.08
    -54.25 (-0.19%)
     

Is It The Right Time To Buy Evoke Pharma Inc (EVOK)?

Evoke Pharma Inc (NASDAQ:EVOK), a pharmaceuticals company based in United States, saw a significant share price rise of over 20% in the past couple of months on the NasdaqCM. With many analysts covering the stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price. However, could the stock still be trading at a relatively cheap price? Today I will analyse the most recent data on EVOK’s outlook and valuation to see if the opportunity still exists. See our latest analysis for EVOK

What is EVOK worth?

Good news, investors! EVOK is still a bargain right now. My valuation model shows that the intrinsic value for the stock is $38.3, which is above what the market is valuing the company at the moment. This indicates a potential opportunity to buy low. However, given that EVOK’s share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility.

What does the future of EVOK look like?

NasdaqCM:EVOK Future Profit Nov 7th 17
NasdaqCM:EVOK Future Profit Nov 7th 17

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. EVOK’s earnings over the next few years are expected to increase by 27.75%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.

What this means for you:

Are you a shareholder? Since EVOK is currently undervalued, it may be a great time to accumulate more of your holdings in the stock. With a positive outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current undervaluation.

Are you a potential investor? If you’ve been keeping an eye on EVOK for a while, now might be the time to make a leap. Its prosperous future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy EVOK. But before you make any investment decisions, consider other factors such as the strength of its balance sheet, in order to make a well-informed buy.

Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on Evoke Pharma. You can find everything you need to know about EVOK in the latest infographic research report. If you are no longer interested in Evoke Pharma, you can use our free platform to see my list of over 50 other stocks with a high growth potential.


To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned.